A pill for male contraception, called YCT-529, could soon revolutionize the options available to men. Developed by a California-based laboratory, it has just completed its first series of clinical trials, published in Communications Medicine. Tested on 16 healthy men aged 32 to 59, the product caused no side effects on libido, testosterone, mood, or heart rate.
This new treatment works by temporarily blocking a key protein in sperm production, without the use of hormones, unlike the female contraceptive pill. Before human trials, several tests on animals—mice, primates, rats, and dogs—had already demonstrated its efficacy, safety, and reversibility.
The next phase of trials involves daily doses for periods of 28 to 90 days. If the results are confirmed, YCT-529 could represent a major breakthrough, as men currently only have condoms and vasectomy as contraceptive methods.
Despite research that began as early as the 1960s, male contraceptive pill projects were long abandoned due to side effects deemed too severe. This new pill could well change the game.
 Frank Verain
|
04/08/2025 | 
